What are the specific molecular mechanisms by which peripheral monocytes cross the BBB in AD?

PARTIALLY ADDRESSED

The debate outlined peripheral immune involvement but failed to address the precise trafficking mechanisms and molecular signals that enable monocyte infiltration. Understanding these pathways is critical for developing targeted interventions to modulate neuroinflammation. Source: Debate session sess_SDA-2026-04-04-frontier-immunomics-e6f97b29 (Analysis: SDA-2026-04-04-frontier-immunomics-e6f97b29)

Priority: 0.90 Domain: neurodegeneration Hypotheses: 0
📊 Landscape Analysis

Landscape Summary: What are the specific molecular mechanisms by which peripheral monocytes cross the BBB in AD? is a 0.9 priority gap in neurodegeneration. It has 0 linked hypotheses with average composite score 0.000. Status: partially_addressed.

Key Unanswered Questions

Key Researchers

Colonna, Sevlever, et al. (TREM2 biology)

Clinical Trials

What are the specific molecular mechanisms by which peripheral monocytes cross the BBB in AD? — INVOKE-2 (completed)

📈 Living Dashboards
0
Hypotheses
0.000
Top Score
0.000
Avg Score
0
Debates
0.00
Avg Quality
60%
Resolution
0
Mechanistic Families
Gap Resolution Progress60%

Hypothesis Score Distribution

🏆 Competing Hypotheses (Ranked by Score)

No hypotheses linked to this gap yet.

🌊 Knowledge Graph Connections

alleviates (1)

autophagy→BBB

associated with (15)

entities-histone-methylation→ADentities-atp7b-gene→ADentities-ros→ADTAU→ADTDP-43→AD
▸ Show 10 more

biomarker for (1)

tau cleavage products→AD

causes (7)

AD→neurodegenerationPHOSPHORYLATED_TAU→ADBETA_AMYLOID→ADAD→IMMUNE_TOLAD→DEMENTIA
▸ Show 2 more

cross disease mechanism in (5)

MAPT→ADTREM2→ADNLRP3→ADPINK1→ADGRN→AD

depleted in (1)

SPM_levels→AD

disrupts (1)

CLDNs→BBB

inhibits (1)

trehalose→BBB

prevents (1)

NAD+ augmentation→AD

protective against (1)

cognitive stimulation→AD

protects against (1)

ENDOTHELIAL CELLS→BBB

regulates (3)

CLDN5→BBBCLAUDIN5→BBBAUTOPHAGY→BBB

risk factor for (4)

genetically at-risk individuals→ADAPOE ε4→ADmicroglial priming→ADAPOE4→AD

targets (1)

resveratrol→AD

therapeutic target for (6)

TREM2→ADCCR2→ADlevetiracetam→ADSaracatinib→ADanti-amyloid antibodies→AD
▸ Show 1 more

traffics across (1)

Peripheral monocytes→BBB
🕑 Activity Feed
✏ update on knowledge_gap by None 2026-04-25T22:15
✏ update on knowledge_gap by None 2026-04-21T14:21
✏ update on knowledge_gap by None 2026-04-13T11:41
✏ update on knowledge_gap by None 2026-04-13T11:41
💬 Discussion

No discussions yet. Be the first to comment.

📋 Investigation Sub-Tasks

Create sub-tasks to investigate specific aspects of this gap:

  • Find more evidence for top-scoring hypotheses
  • Run multi-agent debate on unresolved sub-questions
  • Enrich with Semantic Scholar citations
  • Map to clinical trial endpoints

← Back to All Gaps